Caption Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Caption Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,000	Closed	-$16.9M	–	1988
2025 Q3	$16.9M	Sell	30,000 -30,000	-50%	-$17M	0.13%	169
2025 Q2	$31.5M	Buy	+60,000	New	+$33.5M	0.35%	50
2024 Q4	–	Sell	-14,000	Closed	-$14.7M	–	1775
2024 Q3	$14.7M	Hold	14,000	–	–	0.23%	101
2024 Q2	$14.7M	Buy	+14,000	New	+$13.6M	0.23%	95
2024 Q1	–	Sell	-10,000	Closed	-$8.78M	–	1608
2023 Q4	$8.78M	Buy	+10,000	New	+$8.23M	0.12%	202
2023 Q2	–	Sell	-25,100	Closed	-$20.6M	–	1349
2023 Q1	$20.6M	Buy	+25,100	New	+$18.9M	0.4%	55
2021 Q3	–	Sell	-9,000	Closed	-$5.03M	–	1753
2021 Q2	$5.03M	Buy	+9,000	New	+$4.56M	0.07%	362
2021 Q1	–	Sell	-1,800	Closed	-$869K	–	1329
2020 Q4	$869K	Buy	+1,800	New	+$972K	0.02%	641
2020 Q2	–	Sell	-15,000	Closed	-$7.32M	–	1151
2020 Q1	$7.32M	Buy	+15,000	New	+$6.19M	0.41%	48
2019 Q3	–	Sell	-7,500	Closed	-$2.35M	–	864
2019 Q2	$2.35M	Buy	+7,500	New	+$2.5M	0.12%	227

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Caption Management's REGN Position: Q3 2025 in Review

Caption Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 31,200 shares — an estimated $17.6M sold.

Caption Management first reported a position in REGN in Q2 2019 and held it in 5 quarters. The position peaked at $16.4M in Q2 2025. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Caption Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Caption Management sold 31,200 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $17.6M.
Caption Management first reported a position in Regeneron Pharmaceuticals in Q2 2019 and held it in 5 quarters.
Caption Management's Regeneron Pharmaceuticals position peaked at $16.4M in Q2 2025.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.